Analysts Set Doximity, Inc. (NASDAQ:DOCS) Price Target at $64.22

Doximity, Inc. (NASDAQ:DOCS) has been given a consensus recommendation of “Moderate Buy” by the twenty-one analysts that are currently covering the stock, MarketBeat.com reports. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $64.22.

Several analysts have issued reports on DOCS shares. Bank of America boosted their target price on shares of Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Piper Sandler raised shares of Doximity from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $31.00 to $78.00 in a research note on Friday, February 7th. Mizuho boosted their price target on shares of Doximity from $55.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Canaccord Genuity Group boosted their price target on shares of Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Doximity from $30.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 21st.

Doximity Stock Up 4.2 %

Shares of NASDAQ:DOCS opened at $63.33 on Wednesday. The company’s fifty day moving average is $63.63 and its two-hundred day moving average is $52.49. Doximity has a 12-month low of $22.96 and a 12-month high of $85.21. The company has a market cap of $11.82 billion, a P/E ratio of 63.33, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34.

Insiders Place Their Bets

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the transaction, the director now owns 6,360 shares of the company’s stock, valued at $366,463.20. The trade was a 75.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 37.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC lifted its position in Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock worth $29,000 after acquiring an additional 440 shares during the last quarter. UMB Bank n.a. raised its position in shares of Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after buying an additional 235 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Doximity by 49.4% during the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock valued at $40,000 after buying an additional 250 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Doximity by 324.2% during the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after buying an additional 603 shares during the last quarter. Finally, Optimum Investment Advisors acquired a new position in shares of Doximity during the fourth quarter valued at about $43,000. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.